Merck's earnings call revealed a cautious outlook, particularly regarding GARDASIL sales, which are negatively impacted by the slowdown in the U.S. market and the challenges in vaccinating the 19-26 age group, leading to reduced 2009 guidance. However, the call highlighted efforts to improve efficiency, restructure the company, and invest in new products and strategies to handle economic headwinds. The tone suggests the company is navigating a difficult economic situation and working to adapt, which could lead to mixed short-term stock performance.
[-1]
